GW Pharmaceuticals to Present at the Piper Jaffray 27th Annual Healthcare Conference
November 24 2015 - 01:00PM
GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW" or "the
Company"), a biopharmaceutical company focused on discovering,
developing and commercializing novel therapeutics from its
proprietary cannabinoid product platform, today announced that
Justin Gover, GW's Chief Executive Officer, will present at the
Piper Jaffray 27th Annual Healthcare Conference to be held at the
Lotte New York Palace Hotel in New York City on Wednesday, 2
December at 11:30 a.m. EST.
A live audio webcast of the presentation will be available
through GW's corporate website in the investor relations section
from the investor's calendar of events page at
www.gwpharm.com. A replay will be available soon
after the live presentation.
About GW Pharmaceuticals plc
Founded in 1998, GW is a biopharmaceutical company focused on
discovering, developing and commercializing novel therapeutics from
its proprietary cannabinoid product platform in a broad range of
disease areas. GW commercialized the world's first plant-derived
cannabinoid prescription drug, Sativex®, which is approved for the
treatment of spasticity due to multiple sclerosis in 27 countries
outside the United States. GW is advancing an orphan drug program
in the field of childhood epilepsy with a focus on Epidiolex®,
which is in Phase 3 clinical development for the treatment of
Dravet syndrome and Lennox-Gastaut syndrome and which is also
expected to enter Phase 3 clinical trials in the treatment of
Tuberous Sclerosis Complex. GW has a deep pipeline of additional
cannabinoid product candidates which includes Sativex in Phase 3
clinical development as a potential treatment of pain associated
with advanced cancer, as well as compounds in Phase 1 and 2 trials
for glioma, type 2 diabetes, and schizophrenia. For further
information, please visit www.gwpharm.com.
CONTACT: GW Pharmaceuticals plc
Stephen Schultz, VP Investor Relations (U.S.)
(Today) +44 20 3727 1000
917 280 2424 / 401 500 6570
FTI Consulting (Media Enquiries)
Ben Atwell / Simon Conway
+ 44 20 3727 1000
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Feb 2024 to Mar 2024
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Mar 2023 to Mar 2024